NGR‐Modified CAF‐Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma
Advanced Science · 2025-03 · 12 (12)
DOI: 10.1002/advs.202410918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.01.2025. Verfasst von Jianxin Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China. Hauptthemen laut MEDLINE: Osteosarcoma, Drug Resistance, Neoplasm, Ferroptosis, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Taishan Young Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Osteosarcoma (OS) chemoresistance presents a significant clinical challenge. This study aims to investigate the potential of using tumor vascular‐targeting peptide NGR‐modified cancer‐associated fibroblasts (CAFs)‐derived exosomes (exos) to deliver circ_0004872‐encoded small peptides promoting autophagy‐dependent ferroptosis to reverse chemoresistance in OS. Through combined single‐cell transcriptome analysis and high‐throughput sequencing, it identified circ_0004872 associated with chemoresistance. Subsequent experiments demonstrated that the small peptide encoded by this Circular RNA (circRNA) can effectively reverse chemoresistance by enhancing OS cell sensitivity to chemotherapy via the mechanism of promoting autophagy‐dependent ferroptosis. Moreover, in vitro and in vivo results confirmed the efficient delivery of NGR‐modified CAFs‐derived exo‐packaged circ_0004872‐109aa to tumor cells, thereby improving targeted therapy efficacy. This study not only offers a novel strategy to overcome chemoresistance in OS but also highlights the potential application value of utilizing exos for drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
- Department of Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, China.
- State Key Laboratory of Reproductive Medicine and Offspring Health, Nanjing Medical University, Nanjing, 211166, China.
- Department of Orthopedics, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, 255036, China.
- School of Medical Laboratory, Shandong Second Medical University, Weifang, 261042, China.
- Department of Orthopedics, Nanjing Jiangbei Hospital, Nanjing, 210044, China.
ORCID-Profile: Peiqing Zhao
Förderung
- Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Taishan Young Scholar Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Du, J., Meng, X., Yang, M., Chen, G., Li, J., Zhu, Z., Wu, X., Hu, W., Tian, M., Li, T., Ren, S., & Zhao, P. (2025). NGR‐Modified CAF‐Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma. Advanced Science, 12(12). https://doi.org/10.1002/advs.202410918
Vancouver
Du J, Meng X, Yang M, Chen G, Li J, Zhu Z, et al. NGR‐Modified CAF‐Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma. Advanced Science. 2025;12(12). doi:10.1002/advs.202410918
BibTeX
@article{Du2025,
author = {Du, Jianxin and Meng, Xiangwei and Yang, Minghao and Chen, Guancheng and Li, Jigang and Zhu, Zengjun and Wu, Xuanxuan and Hu, Wei and Tian, Maojin and Li, Tao and Ren, Shuai and Zhao, Peiqing},
title = {NGR‐Modified CAF‐Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {12},
doi = {10.1002/advs.202410918}
}
EUVIMED